DK1747001T3 - Styring af gennebrudsblødninger i udvidet hormonale svangerskabsforebyggende program - Google Patents
Styring af gennebrudsblødninger i udvidet hormonale svangerskabsforebyggende program Download PDFInfo
- Publication number
- DK1747001T3 DK1747001T3 DK05740127.5T DK05740127T DK1747001T3 DK 1747001 T3 DK1747001 T3 DK 1747001T3 DK 05740127 T DK05740127 T DK 05740127T DK 1747001 T3 DK1747001 T3 DK 1747001T3
- Authority
- DK
- Denmark
- Prior art keywords
- days
- bleeding
- woman
- drospirenone
- extended
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Diabetes (AREA)
- Pregnancy & Childbirth (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Indole Compounds (AREA)
- Steroid Compounds (AREA)
Claims (4)
1. Anvendelse af 20 pg ethinylestradiol og 3 mg drospirenon til fremstilling af et lægemiddel til kvindelig oral svangerskabsforebyggelse, der omfatter et fleksibelt, udvidet program, hvilket program omfatter: a) indgivelse til kvinden af 20 pg ethinylestradiol og 3 mg drospirenon dagligt i en første indgivelsesperiode på 24 dage b) efterfølgende indgivelse til kvinden af 20 pg ethinylestradiol og 3 mg drospirenon dagligt i en anden indgivelsesperiode på: 96 dage, hvorved kvinden umiddelbart efter de 96 dage påbegynder en hormonfri fase på 4 dage, eller mindre end 96 dage, hvis kvinden under den anden indgivelsesperiode oplever tre på hinanden følgende dages gennembrudsblødning eller pletblødning, hvorved kvinden umiddelbart efter de tre på hinanden følgende dage påbegynder en hormonfri fase på 4 dage, og c) efter den hormonfrie fase, indgivelse af 20 pg ethinylestradiol og 3 mg drospirenon til kvinden i overensstemmelse med a) og b) ovenfor.
2. Anvendelse ifølge krav 1, hvorved kvinden påbegynder den hormonfrie fase, når gennembrudsblødning indtræffer.
3. 20 pg ethinylestradiol og 3 mg drospirenon til anvendelse ved styring af uacceptabel blødning, som er gennembrudsblødning eller pletblødning, under kvindelig oral svangerskabsforebyggelse, der omfatter et fleksibelt, udvidet program, hvilket program omfatter: a) indgivelse til kvinden af 20 pg ethinylestradiol og 3 mg drospirenon dagligt i en første indgivelsesperiode på 24 dage b) efterfølgende indgivelse til kvinden af 20 pg ethinylestradiol og 3 mg drospirenon dagligt i en anden indgivelsesperiode på: 96 dage, hvorved kvinden umiddelbart efter de 96 dage påbegynder en hormonfri fase på 4 dage, eller mindre end 96 dage, hvis kvinden under den anden indgivelsesperiode oplever tre på hinanden følgende dages gennembrudsblødning eller pletblødning, hvorved kvinden umiddelbart efter de tre på hinanden følgende dage påbegynder en hormonfri fase på 4 dage, og c) efter den hormonfrie fase, indgivelse af 20 pg ethinylestradiol og 3 mg drospirenon til kvinden i overensstemmelse med a) og b) ovenfor.
4. 20 pg ethinylestradiol og 3 mg drospirenon til anvendelse ifølge krav 3, hvorved kvinden påbegynder den hormonfrie fase, når gennembrudsblødning indtræffer.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56644304P | 2004-04-30 | 2004-04-30 | |
US57502404P | 2004-05-28 | 2004-05-28 | |
US57719904P | 2004-06-07 | 2004-06-07 | |
US63838004P | 2004-12-27 | 2004-12-27 | |
US66006805P | 2005-03-10 | 2005-03-10 | |
PCT/EP2005/004777 WO2005105103A2 (en) | 2004-04-30 | 2005-04-29 | Management of breakthrough bleeding in extended hormonal contraceptive regimens |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1747001T3 true DK1747001T3 (da) | 2019-02-04 |
Family
ID=35056905
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK05740127.5T DK1747001T3 (da) | 2004-04-30 | 2005-04-29 | Styring af gennebrudsblødninger i udvidet hormonale svangerskabsforebyggende program |
Country Status (29)
Country | Link |
---|---|
US (3) | US8163721B2 (da) |
EP (1) | EP1747001B1 (da) |
JP (4) | JP2007535519A (da) |
KR (4) | KR20070004919A (da) |
CN (1) | CN103127156A (da) |
AR (1) | AR048722A1 (da) |
AU (1) | AU2005237255B2 (da) |
BR (1) | BRPI0510493A (da) |
CA (1) | CA2562296A1 (da) |
CR (1) | CR8709A (da) |
DK (1) | DK1747001T3 (da) |
EA (2) | EA031227B1 (da) |
EC (1) | ECSP066999A (da) |
ES (1) | ES2704999T3 (da) |
HU (1) | HUE041475T2 (da) |
IL (1) | IL178458A (da) |
LT (1) | LT1747001T (da) |
MX (1) | MXPA06012567A (da) |
MY (1) | MY151322A (da) |
NO (1) | NO341685B1 (da) |
NZ (1) | NZ586107A (da) |
PA (1) | PA8631801A1 (da) |
PE (1) | PE20060467A1 (da) |
SG (2) | SG152288A1 (da) |
SI (1) | SI1747001T1 (da) |
SV (1) | SV2006002100A (da) |
TW (1) | TWI374735B (da) |
UY (1) | UY28875A1 (da) |
WO (1) | WO2005105103A2 (da) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020132801A1 (en) * | 2001-01-11 | 2002-09-19 | Schering Aktiengesellschaft | Drospirenone for hormone replacement therapy |
MY151322A (en) | 2004-04-30 | 2014-05-15 | Bayer Ip Gmbh | Management of breakthrough bleeding in extended hormonal contraceptive regimens |
US20070111975A1 (en) | 2004-10-07 | 2007-05-17 | Duramed Pharmaceuticals, Inc. | Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens |
US20070088010A1 (en) * | 2005-10-17 | 2007-04-19 | Doris Huebler | Method of making a single-stage pharmaceutical preparation for oral therapy of dysfunctional uterine bleeding, containing ethinyl estradiol and dienogest |
EP1977752A1 (de) * | 2007-03-01 | 2008-10-08 | Bayer Schering Pharma Aktiengesellschaft | Pharmazeutische Zubereitung zur Verminderung der Endometriose |
DE102007011105A1 (de) * | 2007-03-02 | 2008-09-04 | Bayer Schering Pharma Aktiengesellschaft | Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose |
WO2010033188A2 (en) * | 2008-09-16 | 2010-03-25 | Playtex Products, Llc. | Dosages for menstrual suppression, contraception, and hormone replacement therapy, and methods of administering same |
CA2740004A1 (en) | 2008-10-08 | 2010-04-15 | Agile Therapeutics, Inc. | Transdermal delivery |
WO2010042612A1 (en) | 2008-10-08 | 2010-04-15 | Agile Therapeutics, Inc. | Transdermal delivery |
EP2343963B1 (en) | 2008-10-08 | 2019-04-10 | Agile Therapeutics, Inc. | Transdermal delivery |
EP2410859A4 (en) | 2009-03-27 | 2013-03-13 | Agile Therapeutics Inc | TRANSDERMAL ADMINISTRATION |
US10849857B2 (en) | 2010-07-28 | 2020-12-01 | Laboratorios Leon Farma Sa | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
US11351122B1 (en) | 2010-07-28 | 2022-06-07 | Laboratorios Leon Farma Sa | Synthetic progestogens and pharmaceutical compositions comprising the same |
AR081670A1 (es) | 2010-06-29 | 2012-10-10 | Leon Farma Sa Lab | Composicion farmaceutica que comprende drospirenona y kit anticonceptivo |
US9603860B2 (en) | 2010-07-28 | 2017-03-28 | Laboratorios Leon Farma Sa | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
EP2383279A1 (en) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
NO3106148T3 (da) | 2015-06-18 | 2018-08-11 | ||
EP3701944B1 (en) | 2015-06-18 | 2021-12-08 | Estetra SRL | Orodispersible dosage unit containing an estetrol component |
MD3310345T2 (ro) | 2015-06-18 | 2021-07-31 | Estetra Sprl | Comprimată orodispersabilă ce conține estetrol |
MD3310346T2 (ro) | 2015-06-18 | 2021-06-30 | Estetra Sprl | Comprimată orodispersabilă ce conține estetrol |
DK3313408T3 (da) * | 2015-06-23 | 2024-01-29 | Laboratorios Leon Farma Sa | Drospirenon-baseret svangerskabsforebyggende middel til en kvindelig patient, som lider af overvægt |
CA3178291A1 (en) | 2016-08-05 | 2018-04-12 | Estetra Srl | Method for the management of dysmenorrhea and menstrual pain |
HRP20220708T1 (hr) | 2016-09-30 | 2022-07-22 | Myovant Sciences Gmbh | Postupci liječenja fibroida maternice i endometrioze |
TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
JOP20200260A1 (ar) | 2018-04-19 | 2019-10-19 | Estetra Sprl | مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5244096A (en) | 1988-04-22 | 1993-09-14 | Stoner Fred L | Preventive treatment kit against sexually transmitted disease |
WO1993013801A1 (en) | 1992-01-17 | 1993-07-22 | The Procter & Gamble Company | Treatment for atherosclerosis |
DE4344462C2 (de) * | 1993-12-22 | 1996-02-01 | Schering Ag | Zusammensetzung für die Empfängnisverhütung |
US5552394A (en) | 1994-07-22 | 1996-09-03 | The Medical College Of Hampton Roads | Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy |
US6451778B1 (en) * | 1996-07-26 | 2002-09-17 | Wyeth | Oral contraceptive |
JP2000515890A (ja) | 1996-07-26 | 2000-11-28 | アメリカン・ホーム・プロダクツ・コーポレイション | プロゲスチンとエストロゲンとの混合剤からなる一相性避妊法およびキット |
US5842441A (en) | 1996-08-26 | 1998-12-01 | Pharmalett Denmark A/S | Medicated and individualized treatment shampoo for dermatological disturbances of companion animals |
US5898032A (en) | 1997-06-23 | 1999-04-27 | Medical College Of Hampton Roads | Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy |
DE19739916C2 (de) * | 1997-09-11 | 2001-09-13 | Hesch Rolf Dieter | Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen |
US6787531B1 (en) * | 1999-08-31 | 2004-09-07 | Schering Ag | Pharmaceutical composition for use as a contraceptive |
KR101019361B1 (ko) | 1999-08-31 | 2011-03-07 | 바이엘 쉐링 파마 악티엔게젤샤프트 | 피임약으로서의 사용을 위한 에티닐에스트라디올과드로스피렌온의 약학적 조합 |
CO5271709A1 (es) | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos |
US6653298B2 (en) * | 2000-01-14 | 2003-11-25 | Sterix Limited | Composition |
DE10045380A1 (de) * | 2000-09-14 | 2002-04-04 | Schering Ag | Verfahren zur Kontrazeption und dessen Darreichungsform |
TWI303990B (en) | 2000-10-17 | 2008-12-11 | Pfizer Prod Inc | New use of estrogen agonists/antagonists for improving vascular health |
US20020193356A1 (en) * | 2001-05-23 | 2002-12-19 | Van Beek Agatha Antonia Magdalena | Means and method for hormonal contraception |
US20030018018A1 (en) | 2001-07-10 | 2003-01-23 | Medical College Of Hampton Roads | Ultra low dose oral contraceptives with sustained efficacy and induced amenorrhea |
MY151322A (en) * | 2004-04-30 | 2014-05-15 | Bayer Ip Gmbh | Management of breakthrough bleeding in extended hormonal contraceptive regimens |
US8501720B2 (en) | 2004-07-30 | 2013-08-06 | Bayer Pharma AG | Method for treatment of dysmenorrhea |
-
2005
- 2005-04-19 MY MYPI20051728 patent/MY151322A/en unknown
- 2005-04-27 UY UY28875A patent/UY28875A1/es active IP Right Grant
- 2005-04-29 KR KR1020067022523A patent/KR20070004919A/ko not_active Application Discontinuation
- 2005-04-29 WO PCT/EP2005/004777 patent/WO2005105103A2/en active Application Filing
- 2005-04-29 MX MXPA06012567A patent/MXPA06012567A/es active IP Right Grant
- 2005-04-29 TW TW094113795A patent/TWI374735B/zh active
- 2005-04-29 EA EA201200377A patent/EA031227B1/ru not_active IP Right Cessation
- 2005-04-29 SI SI200532240T patent/SI1747001T1/sl unknown
- 2005-04-29 AU AU2005237255A patent/AU2005237255B2/en active Active
- 2005-04-29 LT LTEP05740127.5T patent/LT1747001T/lt unknown
- 2005-04-29 KR KR1020157012286A patent/KR101812160B1/ko active IP Right Grant
- 2005-04-29 EP EP05740127.5A patent/EP1747001B1/en active Active
- 2005-04-29 SG SG200902990-1A patent/SG152288A1/en unknown
- 2005-04-29 DK DK05740127.5T patent/DK1747001T3/da active
- 2005-04-29 NZ NZ586107A patent/NZ586107A/en unknown
- 2005-04-29 JP JP2007509994A patent/JP2007535519A/ja not_active Withdrawn
- 2005-04-29 KR KR1020137001481A patent/KR20130022425A/ko not_active Application Discontinuation
- 2005-04-29 HU HUE05740127A patent/HUE041475T2/hu unknown
- 2005-04-29 SV SV2005002100A patent/SV2006002100A/es unknown
- 2005-04-29 CA CA002562296A patent/CA2562296A1/en not_active Abandoned
- 2005-04-29 SG SG10201701904TA patent/SG10201701904TA/en unknown
- 2005-04-29 EA EA200601908A patent/EA016625B1/ru not_active IP Right Cessation
- 2005-04-29 KR KR1020167035558A patent/KR20160150113A/ko not_active Application Discontinuation
- 2005-04-29 CN CN2012105794658A patent/CN103127156A/zh active Pending
- 2005-04-29 BR BRPI0510493-9A patent/BRPI0510493A/pt not_active Application Discontinuation
- 2005-04-29 ES ES05740127T patent/ES2704999T3/es active Active
- 2005-05-02 US US11/118,779 patent/US8163721B2/en not_active Expired - Fee Related
- 2005-05-02 AR ARP050101738A patent/AR048722A1/es not_active Application Discontinuation
- 2005-05-03 PE PE2005000490A patent/PE20060467A1/es not_active Application Discontinuation
- 2005-05-03 PA PA20058631801A patent/PA8631801A1/es unknown
-
2006
- 2006-10-05 IL IL178458A patent/IL178458A/en active IP Right Grant
- 2006-10-25 CR CR8709A patent/CR8709A/es not_active Application Discontinuation
- 2006-11-13 EC EC2006006999A patent/ECSP066999A/es unknown
- 2006-11-28 NO NO20065499A patent/NO341685B1/no unknown
-
2012
- 2012-04-17 US US13/448,585 patent/US20120202779A1/en not_active Abandoned
- 2012-10-12 JP JP2012227416A patent/JP6134491B2/ja active Active
-
2015
- 2015-03-09 US US14/642,096 patent/US20150174142A1/en not_active Abandoned
- 2015-06-23 JP JP2015126043A patent/JP6153967B2/ja active Active
-
2016
- 2016-12-13 JP JP2016241318A patent/JP2017048253A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1747001T3 (da) | Styring af gennebrudsblødninger i udvidet hormonale svangerskabsforebyggende program | |
US5824667A (en) | Composition for contraception | |
KR100352571B1 (ko) | 배합호르몬피임약제 | |
JPH11508538A (ja) | ホルモン避妊用薬剤の複合調剤、キット及び避妊方法 | |
EP2305266A1 (en) | Extended estrogen dosing contraceptive regimen | |
US5980940A (en) | Pharmaceutical combination preparation for hormonal contraception | |
US20060079491A1 (en) | Method of female hormonal contraception using a fixed extended cycle hormonal preparation containing dienogest and ethinyl estradiol | |
AU2011226911B2 (en) | Management of breakthrough bleeding in extended hormonal contraceptive regimens | |
ZA200609988B (en) | Management of breakthrough bleeding in extended hormonal contraceptive regimens | |
MXPA96004440A (en) | Preparation of a pharmaceutical combination for oven contraception |